Testified at a hearing before the U.S. House of Representatives' Committee on Ways and Means as a neutral ERISA pundit regarding Appropriateness of 401(k) Fees
This event has already occurred.
Related Insights
FDA's New Mandatory Cosmetics Recall Guidance: What You Need to Know
The Appellate Court of Maryland Reaffirms Business Judgment Protections for Directors of a Maryland Corporation in Rejecting an Unsolicited Topping Bid